-
Farletuzumab: Advancing Antibody-Drug Conjugate Research in Ovarian Cancer(Post)
Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epi
ELISA Plate-to-Plate OD Differences: Same-Lot Troubleshooting(Post)Quick answer When plates from the same lot give very different OD values, the cause is almost always a comparison problem, not a manufacturing problem. The three usual culprits are a t
Exosomes - Discovery, Cargo, Biogenesis & Functions(Post)by Ryan Wallis, PhD student, QMUL, Blizard Institute The microscopic world of cell biology was first explored by Robert Hooke in the 17th century and published in his work, Microgra
Protease vs Peptidase: Understanding Enzymatic Digestion(Post)Enzymology · Protein DegradationProtease vs Peptidase: Understanding the DifferenceProteases and peptidases are the enzymes that cleave peptide bonds — breaking proteins down into peptides and peptide
Department of Oncology Retreat 2025(Post)Department of Oncology RetreatAssay Genie was honoured to sponsor and participate in the inaugural 2025 Department of Oncology Retreat, hosted by the University of Lausanne and Lausanne
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
Biomarker Testing: Advancements, Applications, and Future Directions(Post)Biomarkers, measurable indicators of biological processes or responses to therapeutic interventions, play a pivotal role in modern healthcare. They provide clinicians with valuable information
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
Protocole ELISA contre les anticorps hétérophiles en clinique et labo(Post)Protocole ELISA contre les anticorps hétérophiles en clinique et labo Un résultat Elisa qui ne colle pas au tableau clinique évoque d’abord une interférence par anticorps hétérophiles, surtout sur un
Brentuximab: Unveiling the Role of Anti-CD30 in Cancer Research(Post)Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Anti-Corruption Policy(Page) PCR Detection of COVID-19 (SARS-CoV-2)(Post)PCR Detection of COVID-19 (SARS-CoV-2) Contents Background Assay Information Sample Types Upp
Guide to Fluorescence Activated Cell Sorting (FACs): The Latest Technology in Cell Separation(Post)Flow Cytometry · Cell SortingGuide to Fluorescence-Activated Cell Sorting (FACS)Fluorescence-activated cell sorting (FACS) is a specialised form of flow cytometry that physically isolates individual c
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars(Post)Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
Amino Acids: Types, Functions, Structure & Essential Guide(Post)Biochemistry · Protein Guide Amino Acids: Types, Functions, Structure & Essential Guide The 20 standard amino acids are the building blocks of
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
Business Development Manager, UK(Page)